학술논문
152PD - Double-blind, randomized phase III study to compare the efficacy and safety of trastuzumab and its biosimilar candidate CT-P6 in HER2 positive early breast cancer (EBC)
Document Type
Abstract
Author
Source
In Annals of Oncology September 2017 28 Supplement 5:v44-v45
Subject
Language
ISSN
0923-7534